Clinical Trial Update: Tucatinib+Trastuzumab+Eribulin in HER2+ MBC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating tucatinib in combination with trastuzumab and eribulin for HER2-positive breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Halaven (eribulin)
• Tukysa (tucatinib) (tucatinib)

Snippet

Sponsor: Criterium, Inc. | Conditions: Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer | Phase 2 | Status: RECRUITING